| Dr Jamie Marie Lang, DDS | |
|
1425 Wakarusa Dr, Lawrence, KS 66049-3832 | |
| (785) 841-3311 | |
| (785) 843-0421 |
| Full Name | Dr Jamie Marie Lang |
|---|---|
| Gender | Female |
| Speciality | Dentist |
| Location | 1425 Wakarusa Dr, Lawrence, Kansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194038539 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 122300000X | Dentist | 61270 (Kansas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jamie Marie Lang, DDS 1425 Wakarusa Dr, Lawrence, KS 66049-3832 Ph: (785) 841-3311 | Dr Jamie Marie Lang, DDS 1425 Wakarusa Dr, Lawrence, KS 66049-3832 Ph: (785) 841-3311 |
News Archive
Chronic kidney disease (CKD) affects at least one in four Americans who are older than 60 and can significantly shorten lifespan. Yet the few available drugs for CKD can only modestly delay the disease's progress towards kidney failure. Now, however, a team led by researchers at the Perelman School of Medicine at the University of Pennsylvania, has found an aspect of CKD's development that points to a promising new therapeutic strategy.
A new record for original science submissions has been set for the world's leading heart failure congress. In addition to the main abstract programme, highly anticipated results from major studies will be presented in the late breaking trial sessions.
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today announced that study results demonstrated that arimoclomol exhibited both statistically significant neuroprotective and neuroregenerative effects in brain cells of animals induced with stroke, offering important insights into this drug candidate's mechanism of action.
One of the first spectroscopic imaging-based studies of neurological injury in COVID-19 patients has been reported by researchers at Massachusetts General Hospital (MGH) in the American Journal of Neuroradiology.
Alkermes, Inc. today announced that results from the phase 3 clinical study of VIVITROL® (naltrexone for extended-release injectable suspension) in opioid dependence have been published by The Lancet. The six-month, phase 3 trial met its primary endpoint and showed significantly greater opioid-free weeks among patients treated with VIVITROL, compared to placebo.
› Verified 8 days ago
Dr. Rodney C. Brown, DDS, MS Dentist Medicare: Not Enrolled in Medicare Practice Location: 4830 Quail Crest Pl, Lawrence, KS 66049 Phone: 785-843-8610 Fax: 785-843-8611 | |
Dr. Brent Cameron Wood, D.D.S Dentist Medicare: Not Enrolled in Medicare Practice Location: 1425 Wakarusa Dr, Suite C, Lawrence, KS 66049 Phone: 785-856-2483 Fax: 866-614-9189 | |
Dr. Barbara Opsahl Schupp, DDS Dentist Medicare: Medicare Enrolled Practice Location: 346 Maine St, Lawrence, KS 66044 Phone: 785-842-9223 Fax: 785-842-4335 | |
Keith D Van Horn, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 2210 Yale Rd, Lawrence, KS 66049 Phone: 785-842-0705 Fax: 785-865-2324 | |
Dr. Brendan Timothy Farrell, D.D.S. Dentist Medicare: Medicare Enrolled Practice Location: 308 Maine St, Lawrence, KS 66044 Phone: 785-843-5490 | |
Dr. Robert W. Jacobs, D.D.S. Dentist Medicare: Not Enrolled in Medicare Practice Location: 346 Maine St, Lawrence, KS 66044 Phone: 785-842-9223 Fax: 785-842-4335 | |
Ise D'angelo, DMD Dentist Medicare: Not Enrolled in Medicare Practice Location: 3110 Nieder Rd, Lawrence, KS 66047 Phone: 815-289-7615 |